Eli Lilly's Retatrutide Delivers Bariatric-Level 30.3% Weight Loss and Resolves Comorbidities in Phase 3 Trials

Eli Lilly's Retatrutide Delivers Bariatric-Level 30.3% Weight Loss and Resolves Comorbidities in Phase 3 Trials

At the American Diabetes Association (ADA) 2026 Scientific Sessions, Eli Lilly and Company presented groundbreaking Phase 3 data for retatrutide, its investigational once-weekly GIP/GLP-1/glucagon triple hormone receptor agonist. The results from the pivotal TRIUMPH-1 (obesity) and TRANSCEND-T2D-1 (type 2 diabetes) trials demonstrate that retatrutide establishes a new efficacy benchmark in metabolic medicine, with weight loss approaching bariatric surgery levels.

Unprecedented Weight Loss Outcomes

In the pivotal TRIUMPH-1 trial (evaluating 262 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes):

• Over 80 weeks, participants on the 12 mg dose of retatrutide lost an average of 70.3 lbs (28.3%) of their body weight. Those on 9 mg lost an average of 64.4 lbs (25.9%), and those on 4 mg lost 47.2 lbs (19.0%).
• Nearly half (45.3%) of the participants on the 12 mg dose achieved 30% or greater weight loss, a threshold historically reached only via bariatric surgery.
• 65.3% of participants on the high dose achieved a body mass index (BMI) below 30, effectively no longer meeting the clinical criteria for obesity.
• In a pre-specified blinded extension, patients with a baseline BMI of 35 or higher maintained on retatrutide 12 mg through 104 weeks achieved a mean weight loss of 85.0 lbs (30.3%).

The trial showed no weight-loss plateau at week 80, suggesting retatrutide's unique glucagon receptor component drives sustained metabolic activation¹ and fat oxidation (boosting energy expenditure) alongside incretin-mediated appetite suppression.

Resolution of Major Comorbidities

Retatrutide demonstrated massive therapeutic benefits beyond weight reduction:

• Obstructive Sleep Apnea (OSA): Retatrutide reduced moderate-to-severe sleep apnea severity by up to 36.1 events per hour (60.6% reduction).
• Osteoarthritis Pain: Participants saw knee osteoarthritis pain reduced by up to 4.3 points (a 73.1% reduction) on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale.
• Glycemic Control: In the TRANSCEND-T2D-1 trial, type 2 diabetes patients achieved HbA1c reductions of up to 2.0% at 40 weeks, with up to 46% achieving a normal HbA1c level (below 5.7%).

Tolerability and Safety Considerations

While retatrutide's efficacy is unparalleled, its safety profile has highlighted some class-related and novel concerns:

• Common gastrointestinal adverse events included nausea (42.4% in TRIUMPH-1), diarrhea (32.0%), vomiting (25.3%), and constipation (26.1%).
• Discontinuation rates due to adverse events rose with dosage, reaching 11.3% for the 12 mg dose compared to 4.9% for placebo.
• Dysesthesia: A neurological sensory disturbance characterized by unpleasant or painful skin sensitivity occurred in a subset of patients. In the related Phase 3 TRIUMPH-4 trial (completed in December 2025), dysesthesia was reported in more than 20% of patients on the high dose, though most cases in TRIUMPH-1 were mild.

Lilly expects to submit regulatory filings for retatrutide in 2026.